Can-Fite BioPharma is set to start a Phase II exploratory trial of Namodenoson for the treatment of pancreatic cancer.

The open-label study intends to assess the safety and efficacy of Namodenoson in pancreatic cancer patients who previously received at least one systemic treatment.

An oral dose of 25mg Namodenoson will be given twice daily to the patients.

Objective response, progression-free survival and duration of response will be measured as efficacy endpoints of the study.

Disease control (defined as an objective response or stable disease), and overall survival will also be considered as efficacy endpoints.

Institute of Oncology, Rabin Medical Center professor Dr Salomon Stemmer will conduct the study.

Can-Fite CEO Dr Pnina Fishman said: “We’ve seen Namodenoson’s potent anti-cancer effects in treating people with liver cancer and believe that based on recent pre-clinical results, our drug may be equally effective in pancreatic cancer, an indication in need of more effective treatments.”

Can-Fite’s pivotal Phase III study of Namodenoson is also currently underway for advanced liver cancer treatment.

The study demonstrated that advanced liver cancer patient remained cancer-free for six years after starting treatment.

Namodenoson was also evaluated for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis and as a second line treatment for hepatocellular carcinoma.